Insight Molecular DiagnosticIMDX
13F holders, Q3 2025 (September 30)At the end of Q3 2025, 27 institutions reported holding Insight Molecular Diagnostic (IMDX) in their 13F filings, down 3 from Q2 2025. 1 opened new positions and 4 sold out. The largest holders were Broadwood Capital Inc. ($37.9M), AWM Investment Company, Inc. ($9.4M) and Pura Vida Investments, LLC ($3.1M). 3 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio), Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Insight Molecular Diagnostic
- CUSIP
- 68235C206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $35K |
| Exits | 4 | $139K |
All 13F filers, Q2 2025 → Q3 2025: 1,100,604 shares bought and 85,014 shares sold, net +1,015,590 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 27 holders
| Broadwood Capital Inc. | 2.29% | No change | 11,410,100 | $37.9M |
| AWM Investment Company, Inc. | 0.88% | No change | 2,822,530 | $9.4M |
| Pura Vida Investments, LLC | 19.16% | Add +4964.9% | 947,134 | $3.1M |
| Vanguard Group Inc. | 0.00% | Add +0.6% | 486,738 | $1.6M |
| Geode Capital Management, LLC | 0.00% | Add +25.9% | 198,453 | $659K |
| BlackRock, Inc. | 0.00% | Add +1.7% | 87,951 | $292K |
| Millennium Management | 0.00% | Add +318.6% | 73,291 | $243K |
| Morgan Stanley | 0.00% | No change | 62,208 | $207K |
| FNY Investment Advisers, LLC | 0.06% | Add +115.3% | 53,077 | $176K |
| State Street Corp. | 0.00% | Add +114.0% | 41,854 | $139K |
| Northern Trust Corp. | 0.00% | No change | 32,890 | $109K |
| Renaissance Technologies | 0.00% | Reduce -9.6% | 23,600 | $78K |
| Citadel Advisors | 0.00% | Reduce -61.9% | 11,787 | $39K |
| Private Advisor Group, LLC | 0.00% | New | 10,416 | $35K |
| Osaic Holdings, Inc. | 0.00% | Add +788.0% | 11,216 | $29K |
| EverSource Wealth Advisors, LLC | 0.00% | No change | 5,000 | $17K |
| UBS Group AG | 0.00% | Reduce -82.3% | 2,714 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -86.0% | 624 | $2K |
| ORG Partners LLC | 0.00% | Reduce -59.1% | 450 | $1K |
| Bank of America Corp. | 0.00% | Reduce -21.8% | 446 | $1K |
| SBI Securities Co., Ltd. | 0.00% | No change | 185 | $614 |
| JPMorgan Chase & Co. | 0.00% | No change | 154 | $511 |
| BNP Paribas Financial Markets | 0.00% | Reduce -87.4% | 30 | $100 |
| Piscataqua Savings Bank | 0.00% | No change | 25 | $82 |
| Albion Financial Group | 0.00% | No change | 7 | $24 |
| Wells Fargo & Company | 0.00% | No change | 3 | $10 |
| Global Retirement Partners, LLC | 0.00% | No change | 1 | $3 |
"% of holder's portfolio" is IMDX's weight in each manager's 13F, not the share of Insight Molecular Diagnostic the manager owns.